ARS signed a contract with the leading ambitious innovative Russian pharmaceutical company of the full cycle to conduct an open label randomized comparative multicenter clinical study of the efficacy and safety in patients with nonspecific vaginitis caused by Candida in the acute stage of the disease. ARS CRO clinical team plans to recruit 146 patients at six Russian sites. The study will last more than a year. eCRF will be used in the clinical trial to collect and process clinical data. On obtaining clinical research results, ARS will provide the drug registration in Russia.